
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
'ITM and ILL's longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,' commented Dr. Andrew Cavey, CEO of ITM. 'Our priority access to ILL's renowned high-flux irradiation services is incredibly important as the demand for n.c.a. Lutetium-177 grows and as our radiopharmaceutical pipeline evolves.'
The high neutron flux of ILL's reactor provides ITM with a high yield of Lu-177, and allows for a particularly sustainable production of the medical radioisotope by minimizing use of the scarce precursor raw material, Ytterbium-176 (Yb-176). Providing radioisotopes to ITM plays a significant role in enabling geographic and industrial return from ILL to its funding countries, fostering innovation and supporting advancements in radiopharmaceutical research and production.
Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope such as Lutetium-177 or Actinium-225 to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, such as receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, with the goal of destroying tumor tissue. The precise localization enables targeted treatment with potentially minimal impact to healthy surrounding tissue.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com
About the ILL, Institut Laue-Langevin
The ILL is the world-leading facility in neutron science and technology. Delivering the most intense neutron beams in the world to its unparalleled suite of 43 state-of-the-art neutron scattering instruments, the ILL offers a unique tool for probing the heart of matter. Every year, around 1500 international researchers visit the ILL to carry out over 1000 cutting-edge experiments in a variety of disciplines, including physics, chemistry, biology, and material science and engineering. Besides its impact in scientific research and education excellence, the ILL helps drive innovation in the fields of health, energy, the environment and quantum materials. The ILL is engaged in the production of radioisotopes for medical applications since more than 15 years now. A major European project, the ILL was founded in Grenoble in 1967 by France and Germany, joined a few years later by the UK. Today, 13 countries fund the facility for their research communities.
ITM Contact
Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email: [email protected]
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: [email protected]
ILL Contact
Radionuclide Production
Ulli Köster
Phone: (+33) (0)4 76 20 71 54
Email: [email protected]
Communications
Catarina Espirito Santo
Phone: (+33) (0)4 76 20 71 07
Email: [email protected]
Attachment
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
3 hours ago
- Wall Street Journal
TotalEnergies Expects Hit From Lower Oil, Gas Prices
TotalEnergies TTE 0.86%increase; green up pointing triangle said it expects lower oil and gas prices to hit its second-quarter earnings, but anticipates hydrocarbon production to rise. The French energy company joined British peer BP in flagging weaker prices would weigh on its results, while bigger rival Shell said earlier this month that it anticipated its second-quarter performance to be hit by weaker performance in its core integrated gas division.


Fast Company
4 hours ago
- Fast Company
Why it can be good for business to fight with your rival
Earlier this summer, Pepsi did something brands have been doing forever: It took a jab at its rival. In this case, that entailed some snarky satirizing of a popular Coke ad campaign. But it raised an eternal brand-battle question: Is it really a good idea to reference a rival so directly? Under the right circumstances, yes, according to the latest research on that subject in a recent Journal of Marketing Research paper, coauthored by Johannes Berendt, a professor of economics and communication at Hannover University of Applied Sciences and Arts in Germany. His fellow co-authors are Sebastian Uhrich, a professor of sports business administration at the German Sport University Cologne; Abhishek Borah, an associate professor of marketing at INSEAD (Institut Européen d'Administration des Affaires) in France; and Gavin Kilduff, a professor of management and organizations at NYU Stern. For starters, Berendt explains in an email, it's important to distinguish between true rivalry and mere competition: Real rivals not only compete against each other in the marketplace, but they also have a 'special competitive relationship based on a shared history,' he says. This includes McDonald's vs. Burger King, Mercedes vs. BMW, Apple vs. Samsung, and, of course, Coke vs. Pepsi. Researchers call it the ' rivalry reference effect.' 'Consumers know that this is more than just regular competition,' Berendt says. In their studies (which included analyses of 1.5 million social media posts from real brands, as well as controlled experiments involving fictional posts in various brand categories), Berendt and his fellow researchers found that a brand message referencing a rival increases consumer engagement—and can even impact purchase intent. 'Openly contested rivalries have a special appeal,' Berendt adds. 'Messages between rivals are processed differently than between ordinary competitors.' (Remember the chicken sandwich wars a couple of years back? It made sense that Popeye's and Chick-fil-A would scrap on social media, but it felt off when Wendy's butted in.) The super-early-rate deadline for Fast Company's Most Innovative Companies Awards is Friday, July 25, at 11:59 p.m. PT. Apply today.


Bloomberg
4 hours ago
- Bloomberg
French Budget Is a ‘Ticking Bomb' for Euro, ING's Pesole Says
Angst around how France will control its swelling budget deficit is returning to financial markets and may start to dent demand for the euro, according to strategists at ING Groep NV. The common currency touched its weakest level against the dollar in a month on Tuesday as France's minority government revived political tensions with proposals to sharply rein in the deficit, including scrapping two national holidays.